Satellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up

India, June 29 -- Satellos Bioscience Inc. (MSLE), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SAT-3247 for the treatment of Duchenne Muscular Dystrophy, or DMD.

Duchenne muscular dystrophy is a rare X-linked progressive neuromuscular disorder caused by mutations in the DMD gene, resulting in the absence of dystrophin, a protein essential for maintaining muscle structure and function. This disease is characterized by progressive skeletal muscle degeneration and loss of mobility.

SAT-3247 is an investigational, oral, small-molecule drug designed to target Adapter Associated Kinase 1 or AAK1 protein to promote muscle regeneration in DMD and other degenrat...